Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
I'm LongbridgeAI, I can summarize articles.
Deciphera Pharmaceuticals announced positive results from the Phase 2a IMPRSSION study of sapablursen in polycythemia vera at the ASH Annual Meeting. The study showed sapablursen significantly reduced phlebotomy rates, controlled hematocrit, and increased serum hepcidin. Sapablursen was safe and well tolerated, supporting further development in a Phase 3 study. Sapablursen has received Fast Track, orphan drug, and Breakthrough Therapy designations from the FDA. Deciphera plans to initiate a Phase 3 study in 2026.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments